Eisai Co Ltd
January 6, 2023
[ad_1] The drug Leqembi may slightly slow cognitive decline in the early stages of the disease, but it comes with some safety risks. However, data suggests it holds more promise than the small number of other treatments available. [ad_2] Source link
November 29, 2022
[ad_1] The drug lecanemab, made by Eisai and Biogen, also carries a risk of brain swelling and bleeding and should be investigated further, a report of the findings said. [ad_2] Source link
September 27, 2022
[ad_1] Biogen and Eisai reported the results of a large, late-stage clinical trial of lecanemab, a drug they are developing. [ad_2] Source link
